These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
234 related articles for article (PubMed ID: 27161253)
1. IDH1 mutation can be present in diffuse astrocytomas and giant cell glioblastomas of young children under 10 years of age. Ferris SP; Goode B; Joseph NM; Kline CN; Samuel D; Gupta N; Bollen A; Perry A; Mueller S; Solomon DA Acta Neuropathol; 2016 Jul; 132(1):153-5. PubMed ID: 27161253 [No Abstract] [Full Text] [Related]
2. Analysis of the IDH1 codon 132 mutation in brain tumors. Balss J; Meyer J; Mueller W; Korshunov A; Hartmann C; von Deimling A Acta Neuropathol; 2008 Dec; 116(6):597-602. PubMed ID: 18985363 [TBL] [Abstract][Full Text] [Related]
3. A Histologic Low-Grade Glioma with 7 Gain, 10 Loss-A Wolf in Sheep's Clothing. Pollom EL; Soltys SG Int J Radiat Oncol Biol Phys; 2021 Apr; 109(5):1137-1138. PubMed ID: 33714521 [No Abstract] [Full Text] [Related]
4. Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas. Hartmann C; Hentschel B; Wick W; Capper D; Felsberg J; Simon M; Westphal M; Schackert G; Meyermann R; Pietsch T; Reifenberger G; Weller M; Loeffler M; von Deimling A Acta Neuropathol; 2010 Dec; 120(6):707-18. PubMed ID: 21088844 [TBL] [Abstract][Full Text] [Related]
6. DMBT1 homozygous deletion in diffuse astrocytomas is associated with unfavorable clinical outcome. Motomura K; Mittelbronn M; Paulus W; Brokinkel B; Keyvani K; Sure U; Wrede K; Nakazato Y; Tanaka Y; Pierscianek D; Kim YH; Mariani L; Vital A; Ohgaki H J Neuropathol Exp Neurol; 2012 Aug; 71(8):702-7. PubMed ID: 22805772 [TBL] [Abstract][Full Text] [Related]
7. PROX1 is a novel pathway-specific prognostic biomarker for high-grade astrocytomas; results from independent glioblastoma cohorts stratified by age and IDH mutation status. Roodakker KR; Elsir T; Edqvist PD; Hägerstrand D; Carlson J; Lysiak M; Henriksson R; Pontén F; Rosell J; Söderkvist P; Stupp R; Tchougounova E; Nistér M; Malmström A; Smits A Oncotarget; 2016 Nov; 7(45):72431-72442. PubMed ID: 27626492 [TBL] [Abstract][Full Text] [Related]
8. The definition of primary and secondary glioblastoma. Ohgaki H; Kleihues P Clin Cancer Res; 2013 Feb; 19(4):764-72. PubMed ID: 23209033 [TBL] [Abstract][Full Text] [Related]
9. WT1 Clone 6F-H2 Cytoplasmic Expression Differentiates Astrocytic Tumors from Astrogliosis and Associates with Tumor Grade, Histopathology, IDH1 Status, Apoptotic and Proliferative Indices: A Tissue Microarray Study. Abd El-Hafez A; Ismail Hany HSED Asian Pac J Cancer Prev; 2020 Aug; 21(8):2403-2413. PubMed ID: 32856872 [TBL] [Abstract][Full Text] [Related]
10. IDH1 mutation in pediatric gliomas: has it a diagnostic and prognostic value? Buccoliero AM; Castiglione F; Degl'Innocenti DR; Gheri CF; Genitori L; Taddei GL Fetal Pediatr Pathol; 2012 Oct; 31(5):278-82. PubMed ID: 22432788 [TBL] [Abstract][Full Text] [Related]
11. Concomitant IDH wild-type glioblastoma and IDH1-mutant anaplastic astrocytoma in a patient with constitutional mismatch repair deficiency syndrome. Galuppini F; Opocher E; Tabori U; Mammi I; Edwards M; Campbell B; Kelly J; Viel A; Quaia M; Rivieri F; D'Avella D; Arcella A; Giangaspero F; Fassan M; Gardiman MP Neuropathol Appl Neurobiol; 2018 Feb; 44(2):233-239. PubMed ID: 29130549 [No Abstract] [Full Text] [Related]
12. NRF2, DJ1 and SNRX1 and their prognostic impact in astrocytic gliomas. Haapasalo J; Nordfors K; Granberg KJ; Kivioja T; Nykter M; Haapasalo H; Soini Y Histol Histopathol; 2018 Aug; 33(8):791-801. PubMed ID: 29441509 [TBL] [Abstract][Full Text] [Related]
14. Radiological and pathological features associated with IDH1-R132H mutation status and early mortality in newly diagnosed anaplastic astrocytic tumours. Wasserman JK; Nicholas G; Yaworski R; Wasserman AM; Woulfe JM; Jansen GH; Chakraborty S; Nguyen TB PLoS One; 2015; 10(4):e0123890. PubMed ID: 25849605 [TBL] [Abstract][Full Text] [Related]
15. Copy Number Profiling of Brazilian Astrocytomas. Bidinotto LT; Torrieri R; Mackay A; Almeida GC; Viana-Pereira M; Cruvinel-Carloni A; Spina ML; Campanella NC; Pereira de Menezes W; Clara CA; Becker AP; Jones C; Reis RM G3 (Bethesda); 2016 Jul; 6(7):1867-78. PubMed ID: 27172220 [TBL] [Abstract][Full Text] [Related]
16. A rare case of a molecular "adult-type" diffuse astrocytoma arising in a child. Pegolo E; Tosolini R; Nardini N; Passone E; Cogo P Childs Nerv Syst; 2018 Feb; 34(2):191-193. PubMed ID: 29198071 [No Abstract] [Full Text] [Related]
17. Reliability of noncontrast-enhancing tumor as a biomarker of IDH1 mutation status in glioblastoma. Lasocki A; Tsui A; Gaillard F; Tacey M; Drummond K; Stuckey S J Clin Neurosci; 2017 May; 39():170-175. PubMed ID: 28214089 [TBL] [Abstract][Full Text] [Related]
18. WT1 expression increases with malignancy and indicates unfavourable outcome in astrocytoma. Rauscher J; Beschorner R; Gierke M; Bisdas S; Braun C; Ebner FH; Schittenhelm J J Clin Pathol; 2014 Jul; 67(7):556-61. PubMed ID: 24607494 [TBL] [Abstract][Full Text] [Related]
19. IDH1 R132H mutation in a pilocytic astrocytoma: a case report. Behling F; Steinhilber J; Tatagiba M; Bisdas S; Schittenhelm J Int J Clin Exp Pathol; 2015; 8(9):11809-13. PubMed ID: 26617931 [TBL] [Abstract][Full Text] [Related]
20. MET gain in diffuse astrocytomas is associated with poorer outcome. Pierscianek D; Kim YH; Motomura K; Mittelbronn M; Paulus W; Brokinkel B; Keyvani K; Wrede K; Nakazato Y; Tanaka Y; Mariani L; Vital A; Sure U; Ohgaki H Brain Pathol; 2013 Jan; 23(1):13-8. PubMed ID: 22672415 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]